Gedeon Richter (RICHTER) investor relations material

Executive summary

• Revenue grew 10.7–11% year-over-year in H1 2025, with strong momentum in Q2 and performance tracking in line with annual guidance, led by women's health and neuropsychiatry.

• Clean EBIT rose 14.5–15.1% year-over-year, driven by CNS and WHC segments, while net profit declined 13–13.2% due to FX losses.

• Free cash flow remained robust at HUF 110–121bn, with most paid as dividends and net cash position stable.

• Advanced innovative pipeline with two phase 2 neuropsychiatry trials and expanded US fertility presence via Granata Bio partnership.

• Continued ESG progress, including a 60% increase in renewable electricity and significant paper usage reduction.

Financial highlights

• H1 2025 revenue up 10.7–11% year-over-year, with FX tailwinds adding 3 percentage points; Clean EBIT up 14.5–15.1%.

• Gross margin stable at 69.7–70.2%; EBIT margin at 30.2%.

• Net profit declined 13–13.2% due to FX losses; EPS fell to HUF 656; ROE at 17%.

• Free cash flow at HUF 110–121bn, nearly unchanged year-over-year.

• Operating expenses up 9.5% year-over-year, below sales growth rate.

Outlook and guidance

• On track to meet full-year guidance of 10% revenue and Clean EBIT growth (CER), FX adjusted.

• Inventory write-offs expected to decline in H2, with full-year costs lower than last year by more than 10%.

• Royalty revenues from Vraylar expected to provide upside, though Medicare pricing headwinds will impact H2.

• FX volatility and global minimum tax implementation remain key factors for H2.

• CapEx and M&A spending are lower, with focus shifting to R&D investment.